Patients with inoperable metastatic melanoma now have another treatment option as ipilimumab becomes the second immunotherapy drug approved by the US Food and Drug Administration (FDA) for the treatment of cancer. Fortunately for clinicians, ipilimumab also has a new, easier-to-pronounce name–Yervoy. Specifically, Yervoy is indicated for patients with unresectable metastatic melanoma that is newly diagnosed or continues to progress despite prior therapy.
Neuroendocrine tumors (NETs) represent a spectrum of rare neoplasms derived from cells of the nervous and endocrine systems.
SAN DIEGO—Omitting adjuvant tamoxifen may not put women aged older than 65 years with early-stage breast cancer at increased risk for local or distant disease recurrence, according to a large, retrospective study presented at the 52nd annual meeting of the American Society for Radiation Oncology.
More than 400 navigators came together for 2 days of education, networking, and professional development, all with the goal of improving oncology patient care and quality of life. At its First Annual Navigation and Survivorship Conference, the Academy of Oncology Nurse Navigators (AONN) welcomed all team members involved in these crucial aspects of patient care—nurses, social workers, lay navigators, navigation and survivorship program administrators—from throughout the country and around the world.
Once-yearly Histrelin Implant Provides Sustained Improvement in Prostate Cancer Patients
BARCELONA—Investigators have documented the long-term efficacy and tolerability of a once-yearly histrelin subdermal implant in men with advanced prostate cancer.
SAN DIEGO—Creative strategies used by local chapters of the Oncology Nursing Society (ONS) to recruit and retain members and reach out to their local communities were described in poster presentations at the 2010 Congress. Using these strategies, the chapters not only increased membership but also strengthened ties with their communities.
San Diego ONS chapter meets goal of 210 by 2010
For patients with relapsed or refractory multiple myeloma (MM), bortezomib-based therapy is effective after lenalidomide plus dexamethasone (LD), according to a Canadian study that evaluated sequencing of novel agents presented at the 51st Annual Meeting and Exposition of the American Society of Hematology.
Nurses from around the world met in Atlanta, Georgia, in March to attend the 16th International Conference on Cancer Nursing, cosponsored by the International Society of Nurses in Cancer Care (ISNCC) and the National Headquarters and South Atlantic Division of the American Cancer Society. The theme of the conference was Enhancing Knowledge, Promoting Quality.
Results 431 - 440 of 440